Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599056 | 0.93 | SCN9A (0.64) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL15599062 | 0.87 | SCN9A (0.60) | SCN9ASCN5ARXRANR1H2NR1H3 | |
| SCHEMBL17423019 | 0.85 | SCN9A (0.82) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL15543308 | 0.84 | SCN9A (0.80) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL19411416 | 0.84 | SCN9A (0.50) | SCN9ARXRANR1H2NR1H3 | |
| SCHEMBL19411386 | 0.83 | SCN9A (0.49) | SCN9ARXRANR1H2NR1H3 | |
| SCHEMBL19429993 | 0.83 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL21075309 | 0.81 | SCN9A (0.44) | SCN9ASCN5ASCN7A | |
| SCHEMBL16759627 | 0.81 | SCN9A (0.51) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL16759257 | 0.81 | SCN9A (0.51) | SCN9ASCN5ASCN1ASCN2ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-2870138-B1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, SNRPD2, RDX | SCN9A 1104/4885SCN5A 724/4885SCN1A 248/4885 |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | BRIX1, SNRPD2, RDX | SCN9A 1104/4885SCN5A 724/4885SCN1A 248/4885 |
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, P2RX3 | SCN9A 501/4885SCN5A 327/4885SCN1A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.